<DOC>
	<DOCNO>NCT02479204</DOCNO>
	<brief_summary>The aim study investigate safety concomitant administration ACT-334441 cardiovascular drug .</brief_summary>
	<brief_title>Clinical Study Investigate Safety Effects Heart Rate , Blood Pressure , Pharmacokinetic Interactions ACT-334441</brief_title>
	<detailed_description>The study consist two part : pilot part ( Part A ) complete prior start main part ( Part B ) . The Subjects participate Part A exclude Part B .</detailed_description>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Signed informed consent Body mass index ( BMI ) 18.0 30.0 kg/m2 ( inclusive ) screening . Women childbearing potential must negative pregnancy test must use reliable method contraception Healthy basis physical examination , cardiovascular assessment laboratory test Pregnant lactate woman Any contraindication study drug History presence disease condition treatment , may put subject risk participation study may interfere absorption , distribution , metabolism excretion study drug Any clinically significant abnormality laboratory test , vital sign , ECG variables pulmonary variable Any circumstance condition , , opinion investigator , may affect subject 's full participation study compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>heart rate</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>